LAWRENCE, Mass., Aug. 29, 2011 /PRNewswire/ -- NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that former NxStage® System One™ patient Tederra Coleman is celebrating the one-year anniversary of her successful kidney transplant. Coleman, 33, of Pompano Beach, Florida, received her transplant after experiencing two years of daily home hemodialysis with the NxStage System One™. Prior to beginning daily home hemodialysis, Coleman spent seven years undergoing thrice-weekly treatments at a dialysis center.
More frequent dialysis with the System One resulted in such a positive change in Coleman's health and quality of life, that she became a certified hemodialysis technician. Her goal is to inform patients about their therapy options, including home hemodialysis with the System One so they can experience the benefits possible with this life changing therapy.
"As an in-center dialysis patient, I didn't like going to the center and the strict schedule was difficult to keep with my job, so I often skipped my treatments, putting my health in jeopardy," said Coleman. "It was my desire to dialyze at home that motivated me to become a compliant patient. Once I began using the System One, I finally felt in control of my life and health and managed my dialysis care properly, which allowed me to become a transplant candidate."
"Recent objective clinical data from large, well designed trials have proven that more frequent hemodialysis with the System One has a positive impact on patient survival, clinical outcomes and quality of life," stated Jeffrey H. Burbank, Chief Executive Officer of NxStage Medical. "We're pleased to celebrate with Tederra and other patients for whom more frequent hemodialysis with the System One not only allows them to live better, healthier lives, but also may better position them for transplant success."
The Tederra Coleman Story
Tederra Coleman was diagnosed with end stage renal disease (ESRD) at the age of 24 upon a visit to her doctor for a regular checkup. Tederra's demanding in-center dialysis schedule eventually forced her to quit her job as a customer service representative.
Coleman learned of NxStage's portable home hemodialysis machine, the System One, in 2008. After completing training with her daughter and trained partner, Ternisha, Coleman began dialyzing at her home five times a week for two hours at a time. The pair typically conducted Tederra's treatments after Ternisha finished her homework. During her time on the System One therapy, Tederra noticed a marked improvement in her energy levels and mental wellbeing.
Tederra had been placed on the kidney transplant list after beginning therapy with the System One. Two years later, in August of 2010, Tederra received a successful kidney transplant.
Today, Tederra is a certified hemodialysis technician. Inspired and intrigued with her mother's therapy, Tederra's daughter, Ternisha, wishes to pursue a career in healthcare and will begin classes this fall at Florida State University College of Medicine.
About the NxStage System One
The NxStage System One is the first and only truly portable hemodialysis system cleared for home use by the U.S. Food & Drug Administration (FDA). Its simplicity and revolutionary size (just over a foot tall) are intended to allow convenient use in patients' homes and give patients the freedom to travel with their therapy. When combined with the NxStage Pureflow SL Dialysis Preparation System, patients are able to further simplify, using ordinary tap water to create dialysis fluid on demand. Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs, at home or on vacation.
About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. NxStage is leading the development of the home hemodialysis market in the US with the only portable hemodialysis machine, the System One, cleared for home use by the FDA. For more information on NxStage and its products, please visit the company's website at http://www.nxstage.com/.
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond NxStage's control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance or achievements including market acceptance and demand for NxStage's System One, growth in home hemodialysis, and certain other factors that may affect future operating results and which are detailed in NxStage's filings with the Securities and Exchange Commission, including Quarterly Report on Form 10Q for the quarter ended June 30, 2011.
In addition, the statements in this press release represent NxStage's expectations and beliefs as of the date of this press release. NxStage anticipates that subsequent events and developments may cause these expectations and beliefs to change. However, while NxStage may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, whether as a result of new information, future events, or otherwise. These forward-looking statements should not be relied upon as representing NxStage's expectations or beliefs as of any date subsequent to the date of this press release.
Kristen K. Sheppard, Esq.
|SOURCE NxStage Medical, Inc.|
Copyright©2010 PR Newswire.
All rights reserved